Coronary side-effect potential of current and prospective antimigraine drugs

被引:265
作者
VanDenBrink, AM
Reekers, M
Bax, WA
Ferrari, MD
Saxena, PR
机构
[1] Erasmus Univ, Dept Pharmacol, NL-3000 DR Rotterdam, Netherlands
[2] Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RA Leiden, Netherlands
关键词
coronary disease; vasoconstriction; migraine; pharmacology; antimigraine drugs;
D O I
10.1161/01.CIR.98.1.25
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-The antimigraine drugs ergotamine and sumatriptan may cause angina-like symptoms, possibly resulting from coronary artery constriction. We compared the coronary vasoconstrictor potential of a number of current and prospective antimigraine drugs (ergotamine, dihydroergotamine, methysergide and its metabolite methylergometrine, sumatriptan, naratriptan, zolmitriptan, rizatriptan, avitriptan). Methods and Results-Concentration-response curves to the antimigraine drugs were constructed in human isolated coronary artery segments to obtain the maximum contractile response (E-max) and the concentration eliciting 50% of E-max (EC50). The EC50 values were related to maximum plasma concentrations (C-max) reported in patients, obtaining C-max/EC50 ratios as an index of coronary vasoconstriction occurring in the clinical setting. Furthermore, we studied the duration of contractile responses after washout of the acutely acting antimigraine drugs to assess their disappearance from the receptor biophase. Compared with sumatriptan, all drugs were more potent (lower EC50 values) in contracting the coronary artery but had similar efficacies (E-max <25% of K+-induced contraction). The C-max of avitriptan was 7- to 11-fold higher than its EC50 value, whereas those of the other drugs were <40% of their respective EC50 values. The contractile responses to ergotamine and dihydroergotamine persisted even after repeated washings, but those to the other drugs declined rapidly after washing. Conclusions-All current and prospective antimigraine drugs contract the human coronary artery in vitro, but in view of low efficacy, these drugs are unlikely to cause myocardial ischemia at therapeutic plasma concentrations in healthy subjects. In patients with coronary artery disease, however, these drugs must remain contraindicated. The sustained contraction by ergotamine and dihydroergotamine seems to be an important disadvantage compared with sumatriptan like drugs.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 49 条
[1]  
BAX WA, 1993, LANCET, V341, P1420
[2]   PHARMACOKINETICS OF METHYSERGIDE AND ITS METABOLITE METHYLERGOMETRINE IN MAN [J].
BREDBERG, U ;
EYJOLFSDOTTIR, GS ;
PAALZOW, L ;
TFELTHANSEN, P ;
TFELTHANSEN, V .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (01) :75-77
[3]   THE SAFETY AND TOLERABILITY OF SUMATRIPTAN - AN OVERVIEW [J].
BROWN, EG ;
ENDERSBY, CA ;
SMITH, RN ;
TALBOT, JCC .
EUROPEAN NEUROLOGY, 1991, 31 (05) :339-344
[4]  
CHESTER AH, 1993, LANCET, V341, P1419, DOI 10.1016/0140-6736(93)90993-Q
[5]   5-HYDROXYTRYPTAMINE RECEPTOR PROFILE IN HEALTHY AND DISEASED HUMAN EPICARDIAL CORONARY-ARTERIES [J].
CHESTER, AH ;
MARTIN, GR ;
BODELSSON, M ;
ARNEKLONOBIN, B ;
TADJKARIMI, S ;
TORNEBRANDT, K ;
YACOUB, MH .
CARDIOVASCULAR RESEARCH, 1990, 24 (11) :932-937
[6]   INTERACTION BETWEEN THROMBOXANE-A2 AND 5-HYDROXYTRYPTAMINE RECEPTOR SUBTYPES IN HUMAN CORONARY-ARTERIES [J].
CHESTER, AH ;
ALLEN, SP ;
TADJKARIMI, S ;
YACOUB, MH .
CIRCULATION, 1993, 87 (03) :874-880
[7]   Naratriptan: Biological profile in animal models relevant to migraine [J].
Connor, HE ;
Feniuk, W ;
Beattie, DT ;
North, PC ;
Oxford, AW ;
Saynor, DA ;
Humphrey, PPA .
CEPHALALGIA, 1997, 17 (03) :145-152
[8]   5-HYDROXYTRYPTAMINE CONTRACTS HUMAN CORONARY-ARTERIES PREDOMINANTLY VIA 5-HT2 RECEPTOR ACTIVATION [J].
CONNOR, HE ;
FENIUK, W ;
HUMPHREY, PPA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 161 (01) :91-94
[9]  
DAHLOF C, 1995, HEADACHE, V35, P292